LoginSignup
Bio Rad logo

Bio Rad

Stock
Stock
Ticker: BIO
BIO

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Bio Rad is $10.16B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Bio Rad is 46.02. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Bio Rad's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $8.254. EPS indicates the company's profitability on a per-share basis.
Currently, 5 analysts cover Bio Rad's stock, with a consensus target price of $352.50. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Bio Rad reported a revenue of $2.59B.
Bio Rad's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $442.80M. EBITDA measures the company's overall financial performance.
Bio Rad has a free cash flow of $353.10M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Bio Rad employs approximately 7,450 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
The free float of Bio Rad is 17.84M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$10.16B
EPS (TTM) 
$8.254
Free Float 
17.84M
P/E ratio (TTM) 
46.02
Revenue (TTM) 
$2.59B
EBITDA (TTM) 
$442.80M
Free Cashflow (TTM) 
$353.10M

Pricing

1D span
$369.16$389.77
52W span
$239.00$395.72

Analyst Ratings

The price target is $352.50 and the stock is covered by 5 analysts.

Buy

1

Hold

2

Sell

2

Information

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. The Life Science segment includes development, manufacturing, and marketing of instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment focuses on designing, manufacturing, marketing, and support of diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Employees
7,450
Industries
Medical Specialties
Sector
Health Care

Identifier

Primary Ticker
BIO

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin